ClinicalTrials.gg
CompletedNCT04930536Updated Nov 22, 2024Results posted

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

A Phase 4 interventional study of Acalabrutinib capsule in Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma, sponsored by AstraZeneca. Completed at 15 sites in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
14th of 39
103 · median 61
Started
2021
with 3 others
Phase 4
Only one
of the 39
Registered
26th of 39
by date
Lead sponsor
7 of 39
AstraZeneca

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 4 that started in 2021, is the only one in phase 4, and was the 26th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,037 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)

Read the detailed description

A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health authority, the current phase-IV study is planned with the aim to assess the safety and efficacy profile of Acalabrutinib in Indian patients with CLL/SLL, and patients with MCL who have received at least one prior therapy. The data obtained from the study will help to understand the safety and efficacy profile of Acalabrutinib in Indian patients. Patients will be monitored throughout the study period for Adverse Events of Acalabrutinib

03

Conditions studied

  • Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the exclusion criteria apply:

  1. Men and Women aged 18yrs or more. 2. (ECOG) performance status of 0,1, or 2 3. Able to receive all outpatient treatments, all laboratory monitoring, and all radiologic evaluations.
  1. The following laboratory parameters:
  1. (ANC) ≥750 cells/μL or ≥500 cells/μL in patients with documented bone marrow involvement, and independent of growth factor support 07 days before the assessment
  2. count ≥50,000 cells/μL or ≥30,000 cells/μL in patients with documented bone marrow involvement, and without transfusion support 07 days before the assessment
  3. (AST) and Alanine transaminase (ALT) ≤2.0 x
  4. Total ≤1.5 x ULN
  5. Estimated of ≥30 mL/min 5. disease defined as achieving less than partial response with the most recent treatment within 6 months before study entry 6. Provision of signed, written and dated prior to any study-specific Procedures 7. The patients of either CLL or MCL:

a. CLL patients: i. Treatment naïve or ≥1 prior systemic therapy for CLL ii. Diagnosis of CD20+ CLL that meets published diagnostic criteria (Hallek et al. 2018) iii. An active disease that meets ≥1 of the following iwCLL 2018 criteria for requiring treatment:

  1. Evidence of progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia. Cut-off levels of \<10 g/dL or platelet counts \<100 × 109/L are generally regarded as an indication for treatment. However, in some patients, platelet counts \<100 × 109/L may remain stable over a long period; this situation does not automatically require therapeutic intervention.
  2. Massive (i.e., ≥6 cm below the left costal margin) or progressive or symptomatic splenomegaly.
  3. Massive nodes (i.e., ≥10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
  4. Progressive lymphocytosis with an increase of ≥50% over a 2-month period or Lymphocyte Doubling Time (LDT) in \<6 months. LDT can be obtained by linear regression extrapolation of absolute lymphocyte counts obtained at intervals of 2 weeks over an observation period of 2 to 3 months; patients with initial blood lymphocyte counts \<30 × 109/L may require a longer observation period to determine the LDT. Factors contributing to lymphocytosis other than CLL (e.g., infections, administration) should be excluded.
  5. complications, including anaemia or thrombocytopenia poorly responsive to corticosteroids.
  6. Symptomatic or functional extra-nodal involvement (e.g., skin, kidney, lung, spine).
  7. Disease-related symptoms as defined by any of the following:

    1. Unintentional weight loss of ≥10% within the previous 06 months.
    2. Significant fatigue (i.e., ECOG performance scale 02 or worse; cannot work or unable to perform usual activities).
    3. Fever ≥100.5°F or 38.0°C for 02 or more weeks without evidence of infection.
    4. Night sweats for ≥1 month without evidence of infection.

    b. MCL Patients: i. Confirmed MCL with translocation t(11;14) (q13;q32) and/or overexpressed cyclin D1 ii. Measurable nodal disease (one or more lesions measuring ≥2 cm in the longest diameter) iii. Relapsed after, or were refractory to, 1-5 previous treatments

Exclusion criteria

Exclusion Criteria:

  1. Known prolymphocytic leukaemia, Central Nervous System (CNS) lymphoma or leukaemia; or known history of (or currently suspected) Richter's syndrome
  2. Treatment with chemotherapy, external beam radiation therapy, anticancer antibodies, or drug within 30 days of the first dose of study drug
  3. Prior radio-conjugated or toxin-conjugated antibody therapy
  4. Anticoagulation therapy (e.g., warfarin or equivalent vitamin K antagonists) within 07 days of the first dose of study drug.
  5. Major surgery ≤30 days before the first dose of study drug
  6. History of stroke or intracranial haemorrhage ≤6 months before the first dose of study drug
  7. History of bleeding diathesis
  8. Prior exposure to a B-cell lymphoma-2 (Bcl-2) inhibitor or B-cell receptor inhibitor like BTKs
  9. Active Cytomegalovirus (CMV) infection or serologic status reflecting active or C infection or known history of infection with (HIV), or any uncontrolled active systemic infection.
  10. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Congestive Heart Failure, or Myocardial Infarction within 06 months of screening, or any Class 3 or 4 cardiac diseases as defined by the Functional Classification, or >480 msec at screening.
  11. Requiring treatment with proton-pump inhibitors (e.g., Omeprazole, Esomeprazole, Lansoprazole, Dexlansoprazole, Rabeprazole, or Pantoprazole).
  12. Breastfeeding or pregnant.
  13. Current life-threatening illness, medical condition, or organ/system dysfunction which, in the Investigator's opinion, could have compromised the subject's safety or put the study at risk.
  14. Concurrent participation in another therapeutic clinical trial.

    -

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Acalabrutinib Capsule

    Single-arm study

    Drug: Acalabrutinib capsule

Interventions

  • The recommended dose of Acalabrutinib is 100 mg given per oral (PO) twice daily

    Also known as: Calquence®

06

What researchers measure

Primary outcomes

  1. Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections

    The AESIs for acalabrutinib, including arrhythmias (atrial fibrillation), anaemia, hypertension, bleeding, and infections, are presented.

    Time frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])

  2. Second Primary Malignancies

    The safety of acalabrutinib was investigated by determining the number of second primary malignancies.

    Time frame: Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])

Secondary outcomes

  1. Objective Response to Treatment

    The efficacy of acalabrutinib was assessed by measuring the participants' objective response to treatment. Objective response = Complete Response (CR) + Partial Response (PR) + Partial Response with lymphocytosis (PRL).

    Time frame: Visit 5 (Day 85) and Visit 8 (Day 170)

  2. Health Related Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQC30] Questionnaire)

    The EORTC QLQ-C30 is a 30-item questionnaire that measures quality of life in cancer patients. It is divided into several scales: Functioning Scales (Physical, Role, Cognitive, Emotional, and Social), Symptom Scales (Fatigue, Pain, Nausea/Vomiting), Dyspnoea, Sleep Disturbances, Appetite Loss, Diarrhoea, Constipation, Financial Difficulties, and Global Health Status/Quality of Life Scale. Scores range from 0 to 100. A higher score indicates better health related quality of life. The total scores were calculated from the mean of the 13 QLQ-C30 scales (Global Quality of Life Scale and Financial Impact Scale were excluded). Prior to calculating the mean, Symptom Scales were reversed to obtain a uniform direction of all scales. The total score was only calculated if all of the required 13 scale scores were available using scale scores based on the completed items, provided that at least 50% of the items in that scale were completed.

    Time frame: From Visit 1 (Day 0), during Visit 5 (Day 85), and at Visit 8 (Day 170)

07

Results

Posted Nov 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneCCL/SLLRelapsed and Refractory MCL
Started9013
Completed828
Not completed85
Withdrew: Adverse event10
Withdrew: Disease progression20
Withdrew: Patient decision42
Withdrew: Death, serious adverse event, screen failure13

Outcome measures

SecondaryObjective Response to Treatment

The efficacy of acalabrutinib was assessed by measuring the participants' objective response to treatment. Objective response = Complete Response (CR) + Partial Response (PR) + Partial Response with lymphocytosis (PRL).

Time frame:
Visit 5 (Day 85) and Visit 8 (Day 170)
Reported as:
Count of participants · Participants
Objective Response to Treatment
ParticipantsCLL/SLLRelapsed and Refractory MCL
Visit 5: CR12
Visit 5: PR533
Visit 5: PRL10
Visit 5: Objective Response555
Visit 8: CR40
Visit 8: PR504
Visit 8: PRL10
Visit 8: Objective Response554
PrimaryAdverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections

The AESIs for acalabrutinib, including arrhythmias (atrial fibrillation), anaemia, hypertension, bleeding, and infections, are presented.

Time frame:
Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])
Reported as:
Number · Events
Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections
EventsCLL/SLLRelapsed and Refractory MCL
Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections00
SecondaryHealth Related Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQC30] Questionnaire)

The EORTC QLQ-C30 is a 30-item questionnaire that measures quality of life in cancer patients. It is divided into several scales: Functioning Scales (Physical, Role, Cognitive, Emotional, and Social), Symptom Scales (Fatigue, Pain, Nausea/Vomiting), Dyspnoea, Sleep Disturbances, Appetite Loss, Diarrhoea, Constipation, Financial Difficulties, and Global Health Status/Quality of Life Scale. Scores range from 0 to 100. A higher score indicates better health related quality of life. The total scores were calculated from the mean of the 13 QLQ-C30 scales (Global Quality of Life Scale and Financial Impact Scale were excluded). Prior to calculating the mean, Symptom Scales were reversed to obtain a uniform direction of all scales. The total score was only calculated if all of the required 13 scale scores were available using scale scores based on the completed items, provided that at least 50% of the items in that scale were completed.

Time frame:
From Visit 1 (Day 0), during Visit 5 (Day 85), and at Visit 8 (Day 170)
Reported as:
Mean · Score on a scale
Health Related Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [EORTC QLQC30] Questionnaire)
Score on a scaleCLL/SLLRelapsed and Refractory MCL
Visit 1 Total Score56.9 ± 12.5257.0 ± 6.46
Visit 5 Total Score56.8 ± 7.8857.9 ± 7.21
Visit 8 Total Score57.9 ± 9.3458.6 ± 6.76
PrimarySecond Primary Malignancies

The safety of acalabrutinib was investigated by determining the number of second primary malignancies.

Time frame:
Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170])
Reported as:
Number · Participants
Second Primary Malignancies
ParticipantsCLL/SLLRelapsed and Refractory MCL
Second Primary Malignancies00

Adverse events

Collected over Throughout study completion, approximately 198 days (from the Screening Phase [Day 0], Treatment Phase [Days 1-170], and until the Follow-up Phase [28 days after Day 170]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CCL/SLL1/89 (1.1%)8/89 (9%)38/89 (42.7%)
Relapsed and Refractory MCL2/11 (18.2%)3/11 (27.3%)7/11 (63.6%)
Most frequent serious events
Most frequent serious events
EventCCL/SLLRelapsed and Refractory MCL
Coronavirus infectionInfections and infestations0/891/11
Subdural haemorrhageInjury, poisoning and procedural complications0/891/11
DyspnoeaRespiratory, thoracic and mediastinal disorders0/891/11
PneumoniaInfections and infestations3/890/11
Myocardial infarctionCardiac disorders2/890/11
PyrexiaGeneral disorders1/890/11
Covid-19 pneumoniaInfections and infestations1/890/11
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/890/11
Most frequent other events
Showing 10 of 79
Most frequent other events
EventCCL/SLLRelapsed and Refractory MCL
Abdominal pain upperGastrointestinal disorders1/891/11
DiarrhoeaGastrointestinal disorders8/891/11
AnaemiaBlood and lymphatic system disorders4/891/11
Coronavirus infectionInfections and infestations0/891/11
RhinitisInfections and infestations0/891/11
Upper respiratory tract infectionInfections and infestations1/891/11
Subdural haemorrhageInjury, poisoning and procedural complications0/891/11
Platelet count decreasedInvestigations0/891/11
Back painMusculoskeletal and connective tissue disorders2/891/11
ThrombocytopeniaBlood and lymphatic system disorders0/891/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CCL/SLLRelapsed and Refractory MCLTotal
Mean61.8 ± 11.260.3 ± 6.961.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)CCL/SLLRelapsed and Refractory MCLTotal
Female18220
Male71980
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CCL/SLLRelapsed and Refractory MCLTotal
American Indian or Alaska Native000
Asian8911100
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

15 sites
  • Research Site
    Ahmedabad, 380009, India
  • Research Site
    Bangalore, 560017, India
  • Research Site
    Bangalore, 560064, India
  • Research Site
    Bengaluru, 560099, India
  • Research Site
    Chandigarh, 160012, India
  • Research Site
    Gurugram, 122001, India
  • Research Site
    Guwahati, 781032, India
  • Research Site
    Hyderabad, 500019, India
  • Research Site
    Hyderabad, 500033, India
  • Research Site
    Kochi, 682041, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Ludhiana, 141 008, India
  • Research Site
    Mumbai, 400010, India
  • Research Site
    Mumbai, 400012, India
  • Research Site
    New Delhi, 110 085, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Clinical study report

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2023, 21 months.

Results were first posted in Nov 2024, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Jul 14, 2021
Primary completionActual
May 2, 2023
CompletionActual
May 2, 2023
Results first posted
Nov 22, 2024
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04930536
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Jul 14, 2021
Primary completion
May 2, 2023
Completion
May 2, 2023
Results posted
Nov 22, 2024
Last update
Nov 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion